ReportGem ReportGem

U.S. COMPANY FILING

AbbVie Inc. — Form 10-Q filed 2026-05-08

Filed: 2026-05-08Company: AbbVie Inc.Ticker: ABBVExchange: NYSEForm: 10-QReport period: 2026-03-31SEC accession: 0001551152-26-000017Event: earningsMateriality: 85

Filing text preview

AbbVie's Q1 2026 net revenues rose 12.4% to $15.0B, but net earnings fell to $695M (EPS $0.39) due to higher contingent consideration fair value changes and acquired IPR&D expenses. The company completed a RemeGen license deal with $650M upfront and issued $8.0B senior notes.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2026-05-08Billionaire Ken Griffin Increased His Position in This Dividend King by 547%2026-08-19AbbVie Inc. Files 8-K Reporting Other Events2026-08-1910-Q2026-08-03 · 10-Q8-K2026-07-31 · 8-K8-K2026-04-29 · 8-KFORM 8-K2026-02-26 · 8-K10-K2026-02-20 · 10-K